Australia markets closed

Aligos Therapeutics, Inc. (5WK.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
0.5420+0.0010 (+0.18%)
As of 08:03AM CEST. Market open.
Currency in EUR

Valuation measures4

Market cap (intra-day) 43.03M
Enterprise value -50.94M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)3.95
Price/book (mrq)0.77
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 2.28
52-week change 3-47.48%
S&P500 52-week change 324.69%
52-week high 31.0300
52-week low 30.5050
50-day moving average 30.7270
200-day moving average 30.6916

Share statistics

Avg vol (3-month) 3479
Avg vol (10-day) 3682
Shares outstanding 575.02M
Implied shares outstanding 679.55M
Float 840.21M
% held by insiders 120.55%
% held by institutions 161.61%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in USD.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-2,235.90%

Management effectiveness

Return on assets (ttm)-42.83%
Return on equity (ttm)-137.79%

Income statement

Revenue (ttm)13.79M
Revenue per share (ttm)0.15
Quarterly revenue growth (yoy)-63.80%
Gross profit (ttm)N/A
EBITDA -84.14M
Net income avi to common (ttm)-99.59M
Diluted EPS (ttm)-0.9600
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)112.74M
Total cash per share (mrq)1.44
Total debt (mrq)10.48M
Total debt/equity (mrq)17.53%
Current ratio (mrq)6.25
Book value per share (mrq)0.79

Cash flow statement

Operating cash flow (ttm)-79.36M
Levered free cash flow (ttm)-47.74M